Jefferies downgraded STAAR Surgical from Buy to Hold
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2026 | $40.00 | Neutral → Outperform | Wedbush |
| 4/9/2026 | $27.00 | Hold → Buy | Canaccord Genuity |
| 2/3/2026 | $26.00 | Neutral | Wedbush |
| 1/16/2026 | $13.00 | Underweight | Morgan Stanley |
| 4/21/2025 | $17.00 | Equal Weight | Wells Fargo |
| 2/12/2025 | Buy → Hold | Jefferies | |
| 2/12/2025 | $45.00 → $17.00 | Outperform → Neutral | Mizuho |
| 2/12/2025 | Buy → Neutral | BTIG Research |
Wedbush upgraded STAAR Surgical from Neutral to Outperform and set a new price target of $40.00
Canaccord Genuity upgraded STAAR Surgical from Hold to Buy and set a new price target of $27.00
Wedbush initiated coverage of STAAR Surgical with a rating of Neutral and set a new price target of $26.00
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that management will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology Forum Date: Tuesday, May 26, 2026 Format: Meetings and Webcast Fireside Chat Details: Investor meeting participation is by invitation only from the sponsoring brokerage firm. Webcast: 4:30 PM ET, Webcast Link Canaccord Genuity Virtual Fireside Chat Date: Wednesday, May 27, 2026 Format: Webcast Fireside Chat Details: Registration for the webcast is by invitation only via the sponsoring brokerage firm. Webcast: 2:3
Net Sales of $93.5 million, highest first quarter Net Sales in Company's history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April 3, 2026. First Quarter 2026 Financial Overview Net sales of $93.5 million, up 119.6% Y/Y Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results in combination with a shareholder letter for the first quarter ended April 3, 2026, on Wednesday, May 13, 2026, after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical First Quarter 2026 Financial Results Webcast Date: Wednesday, May 13, 2026 Time: 5:30 p.m. ET/ 2:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=bNZKMWPv M
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
4 - STAAR SURGICAL CO (0000718937) (Issuer)
10-Q - STAAR SURGICAL CO (0000718937) (Filer)
8-K - STAAR SURGICAL CO (0000718937) (Filer)
DEFA14A - STAAR SURGICAL CO (0000718937) (Filer)
Search Committee Has Initiated a Global Search to Select Next CEO STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that its Board of Directors (the "Board") has appointed Warren Foust, President and Chief Operating Officer, and Deborah Andrews, Chief Financial Officer, as interim co-Chief Executive Officers, effective February 1, 2026. Mr. Foust and Ms. Andrews will work together with the other members of the executive leadership team, with support and guidance from the Board, as they lead the Company and manage its day-to-day operations.
Neal Bradsher and Richard LeBuhn of Broadwood and Christopher Wang of Yunqi Capital have Joined STAAR Board STAAR Chair Elizabeth Yeu and CEO Stephen Farrell have Stepped Down from the Board Farrell will Remain CEO until January 31, 2026 STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, and Broadwood Partners, L.P. and its affiliates ("Broadwood"), which together own 31% of STAAR's outstanding common stock, today announced that Neal C. Bradsher and Richard T. LeBuhn of Broadwood and Christopher Wang of Yunqi Capital, which with its affiliates owns 6.5%
Believes New, Independent, and Experienced Directors Are Needed in Order to Restore Trust in the Board and Confidence in the Go-Shop Process Notes Recently Appended Go-Shop Is Not a Good Substitute for a Full Strategic Alternatives Process Conducted at the Right Time Broadwood Partners, L.P. and its affiliates (collectively, "Broadwood") today commented on the recent filing of amendments to the merger agreement in connection with the proposed sale of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA) to Alcon Inc. ("Alcon") (NYSE:ALC). Neal C. Bradsher, Founder and President of Broadwood, said: "For more than three months, we have been telling the Board of Directors tha
Net Sales of $93.5 million, highest first quarter Net Sales in Company's history, up 119.6% Y/Y Net Income of $5.2 million, with GAAP EPS of $0.10 Adjusted EBITDA1 of $24.4 million, or $0.48 per diluted share Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April 3, 2026. First Quarter 2026 Financial Overview Net sales of $93.5 million, up 119.6% Y/Y Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $
Confident in China Progress and Future Roadmap A Clear Path Toward Sustainable Profitability and Growth Board and Leadership Transitions Support Strategy Execution and Shareholder Value Creation STAAR Interim co-CEOs Issue Letter to Shareholders Earnings Call and Webcast Today at 5:30 PM Eastern STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the fourth quarter and fiscal year ended January 2, 2026. STAAR's Interim co-CEOs will be issuing a Letter to Shareholders after this earnings release, which can be found here: https://investors.staar.com/new
STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that it will release financial results for the fourth quarter and fiscal year ended January 2, 2026, on Tuesday, March 3 after the market close. The Company will also host an earnings call and webcast at 5:30 p.m. ET to discuss its financial results and business progress. Event: STAAR Surgical Fourth Quarter and Fiscal Year 2025 Financial Results Webcast Date: Tuesday, March 3, 2026 Time: 5:30 p.m. ET/ 2:30 p.m. PT Location: https://event.choruscall.com/mediaframe/webcast.html?webcastid=J3bNAuVd Topics on the c
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)
SC 13G/A - STAAR SURGICAL CO (0000718937) (Subject)